EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits

23 Feb 2026
EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits
Two leading experts discussed the role of EGb 761® and digital interventions for patients with mild cognitive impairment (MCI) and dementia, highlighting real-world evidence supporting these approaches, at the inaugural Singapore International SEACURE+Neurocognition Symposium 2025.
Sponsored as an educational program by Schwabe Pharma Asia Pacific Pte Ltd

Resources

MY-SPA-007: EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits

MY-SPA-007: EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits

MY-SPA-007: EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits

MY-SPA-007: EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits